Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04140266
Recruitment Status : Not yet recruiting
First Posted : October 25, 2019
Last Update Posted : October 25, 2019
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
The purpose of this study is to evaluate the safety and drug detection of the dapivirine vaginal ring and oral Truvada in breastfeeding mother-infant pairs.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Dapivirine (DPV) Vaginal Ring (VR)-004 Drug: Truvada Tablet Phase 3

Detailed Description:

This study will evaluate the safety and drug detection of the dapivirine (DPV) vaginal ring (VR) and oral Truvada in breastfeeding mother-infant pairs.

Mother-infant pairs will be randomly assigned to receive either the DPV VR or oral Truvada. Mothers randomized to the DPV VR will use the VR continuously for approximately one month (4 weeks), replacing the VR each month for approximately three months (12 weeks). Mothers using the Truvada tablet will take one tablet by mouth daily for approximately three months (12 weeks).

Study visits will occur at Day 0, Weeks 1 and 2, and Months 1, 2, 3, and 3.5. Study visits may include behavioral assessments; product acceptability assessments; infant feeding assessments; physical examinations; blood, urine, and breast milk collection; and pelvic examination and specimen collection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase 3B, Randomized, Open-Label, Safety, and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs
Estimated Study Start Date : February 28, 2020
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : November 30, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Truvada

Arm Intervention/treatment
Experimental: Group A: Dapivirine (DPV) Vaginal Ring (VR)-004
Mothers will use one DPV VR continuously for approximately one month, replacing the DPV VR each month for approximately three months.
Drug: Dapivirine (DPV) Vaginal Ring (VR)-004
Vaginal ring containing 25 mg of DPV

Experimental: Group B: Truvada Tablet
Mothers will take one Truvada oral tablet daily for approximately three months.
Drug: Truvada Tablet
Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
Other Names:
  • Emtricitabine/Tenofovir Disoproxil Fumarate
  • FTC/TDF




Primary Outcome Measures :
  1. Frequency of all serious adverse events (SAEs) including maternal deaths in both study arms (maternal) [ Time Frame: Measured through Month 3.5 ]
    As defined by the Manual for Expedited Reporting of Adverse Events to the Division of AIDS (DAIDS) (Version 2.0, January 2010)

  2. Frequency of all Grade 3 or higher adverse events (AEs) in both study arms (maternal) [ Time Frame: Measured through Month 3.5 ]
    As defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 and/or Addendum 1 (Female Genital Grading Table for Use in Microbicide Studies [Dated November 2007])

  3. Frequency of all SAEs including infant deaths in both study arms (infant) [ Time Frame: Measured through Month 3.5 ]
    As defined by the Manual for Expedited Reporting of Adverse Events to DAIDS (Version 2.0, January 2010)

  4. Frequency of all Grade 3 or higher AEs in both study arms (infant) [ Time Frame: Measured through Month 3.5 ]
    As defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017

  5. Change in maternal plasma dapivirine (DPV) concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  6. Change in maternal blood emtricitabine triphosphate (FTC-TP) concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  7. Change in maternal blood tenofovir diphosphate (TFV-DP) concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  8. Change in maternal breast milk DPV concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  9. Change in maternal breast milk FTC concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  10. Change in maternal breast milk TFV concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  11. Change in infant plasma DPV concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  12. Change in infant blood FTC-TP concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  13. Change in infant blood TFV-DP concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations


Secondary Outcome Measures :
  1. Frequency of study product use [ Time Frame: Measured through Month 3.5 ]
    Based on participant report, as defined by, for example, missed doses for oral Truvada and VR removal/expulsions [voluntary and involuntary] and duration without VR in vagina

  2. Residual drug levels in returned VRs [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  3. Change in maternal plasma DPV concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  4. Change in maternal blood FTC-TP concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  5. Change in maternal blood TFV-DP concentrations [ Time Frame: Measured through Month 3.5 ]
    Based on laboratory evaluations

  6. Participant willingness to use their assigned study products during breastfeeding in the future (Y/N) [ Time Frame: Measured through Month 3.5 ]
    Based on participant report

  7. Proportion of participants who find their study product to be at least as acceptable as other HIV prevention methods [ Time Frame: Measured through Month 3.5 ]
    Based on participant report



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Weeks and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Inclusion Criteria - Mother

Participant mothers must meet all the following criteria to be eligible for inclusion in the study:

  • Age 18 years or older at Screening, as verified per site Standard Operating Procedures (SOPs).
  • At Enrollment, between 6 to 12 weeks postpartum (verified by birth records and/or similar supportive documentation and defined as between 42 - 84 days after delivery, inclusive).
  • By participant report at Screening and Enrollment, currently exclusively breastfeeding one infant and willing and able to continue exclusively breastfeeding that infant for the duration of their participation in the study.

    • Note: Exclusive breastfeeding will be defined as infant nutrition solely from breast milk, as determined by 7-day recall breastfeeding history. For the purposes of MTN-043, "breastfeeding" refers to all human milk feeding situations when an infant is fed with participant's own human milk whether the milk is received directly from the breast or as expressed milk.
  • Consistently using an effective method of contraception per participant report at Enrollment, and intending to continue use of an effective method for the duration of study participation. Effective methods include contraceptive implants, intrauterine device, injectable progestin, oral contraceptive pills, and surgical sterilization.
  • Able and willing to comply with all study requirements and complete all study procedures.
  • Able and willing to provide the following:

    • Written informed consent to be screened for and to take part in the study.
    • Written informed consent for the breastfed infant to be screened for and take part in the study.
  • Intention to stay within study catchment area for study duration and willingness to give adequate locator information, as defined in site SOPs.
  • At Screening and Enrollment, HIV-uninfected based on HIV testing performed by study staff (per algorithm in the study protocol).
  • At Screening and Enrollment, willing to be randomized at time of enrollment to either of the study products, and to continue study product use for at least 12 weeks.

Inclusion Criteria - Infant

Each mother eligible for MTN-043 will be asked to provide written informed consent for herself and her infant to participate in the study if the infant meets the following criteria:

  • At Screening and Enrollment, infant is exclusively breastfed.

    • Note: Exclusive breastfeeding will be defined as infant nutrition solely from breast milk, as determined by 7-day recall breastfeeding history. For the purposes of MTN-043, "breastfeeding" refers to all human milk feeding situations when an infant is fed with participant's own human milk whether the milk is received directly from the breast or as expressed milk.
  • At Screening and Enrollment, the infant is generally healthy, according to the judgment of the investigator of record (IoR)/designee.
  • At Enrollment, the infant is between the ages of 6 and 12 weeks postpartum (verified by birth records and/or similar supportive documentation with age defined as between 42 - 84 days after delivery, inclusive).

Exclusion Criteria:

Exclusion Criteria - Mother

Mothers who meet any of the following criteria will be excluded from the study:

  • At Screening or Enrollment, breastfeeding infant ineligible for enrollment in the study.
  • At Screening or Enrollment, participant reports any of the following:

    • Known adverse reaction to any of the study products (ever).
    • Known adverse reaction to latex and polyurethane (ever).
    • Post-exposure prophylaxis (PEP) for HIV exposure within 6 months prior to Enrollment.
    • Use of vaginal medications(s) or other vaginal products within five days prior to Enrollment.
    • Non-therapeutic injection drug use in the 12 months prior to Enrollment.
    • History of exposure to any investigational drug(s) during pregnancy, including participation in MTN-042.
  • At Screening or Enrollment, has a positive HIV test.
  • At Screening or Enrollment, Grade 2 or higher breast or genitourinary findings.
  • At Screening or Enrollment, has a positive urinary pregnancy test.
  • At Screening, has any of the following laboratory abnormalities:

    • Positive for hepatitis B surface antigen (HBsAg).
    • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≥ Grade 2.
    • Creatinine ≥ Grade 1.
    • Estimated creatinine clearance ≥ Grade 1 (Cockcroft Gault formula).
  • Diagnosed with urinary tract infection (UTI), pelvic inflammatory disease (PID), sexually transmitted infection (STI) or reproductive tract infection (RTI), requiring treatment per World Health Organization (WHO) Guidelines.

    • Note: Otherwise eligible participants diagnosed during Screening with a UTI, PID or STI/RTI requiring treatment per WHO Guidelines - other than asymptomatic bacterial vaginosis (BV) and asymptomatic vulvovaginal candidiasis - are offered treatment consistent with WHO recommendations and may be enrolled after completing treatment if all symptoms have resolved. If treatment is completed and symptoms have resolved prior to obtaining informed consent for Screening, the participant may be enrolled. Genital warts requiring treatment also must be treated prior to enrollment. Genital warts requiring treatment are defined as those that cause undue burden or discomfort to the participant, including bulky size, unacceptable appearance, or physical discomfort.
  • As determined by the IoR/designee, any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease.
  • Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
  • At Enrollment, participant reports any of the following:

    • Participation in any research study involving drugs, vaccines, or medical devices 30 days or less prior to enrollment.
    • Currently participating in other research studies involving drugs, vaccines, or medical devices.
    • Expected to participate in other research studies involving drugs, vaccines, or medical devices during study participation.

Exclusion Criteria - Infants

  • Has any condition that, in the opinion of the IoR/designee, would preclude eligibility, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

    • Note: Examples of exclusionary infant conditions include clinical evidence of stunting or illness.
  • At Enrollment, according to the report of the mother, any of the following apply for the infant:

    • Infants with birth weight less than 2000g.
    • Participation in any research study involving drugs, vaccines, or medical devices since birth.
    • Currently participating in other research studies involving drugs, vaccines, or medical devices.
    • Expected to participate in other research studies involving drugs, vaccines, or medical devices for the duration of study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04140266


Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Study Chair: Maxensia Owor, MBChB, MMed (Paed), MPH MU-JHU CARE
Study Chair: Lisa Noguchi, PhD, CNM Johns Hopkins Bloomberg School of Public Health
Study Chair: Jennifer Balkus, PhD, MPH Fred Hutchinson Cancer Research Center (FHCRC) - Statistical Center for HIV/AIDS Research and Prevention (SCHARP)

Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT04140266    
Other Study ID Numbers: MTN-043
38591 ( Registry Identifier: DAIDS-ES Registry Number )
First Posted: October 25, 2019    Key Record Dates
Last Update Posted: October 25, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Tenofovir
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Dapivirine
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents